# MAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects (Wallaby)

> **NCT06455826** · PHASE1 · COMPLETED · sponsor: **PYC Therapeutics** · enrollment: 6 (actual)

## Conditions studied

- Retinitis Pigmentosa 11
- Retinal Degeneration
- Eye Diseases
- Retinal Disease
- Retinal Dystrophies

## Interventions

- **DRUG:** VP-001

## Key facts

- **NCT ID:** NCT06455826
- **Lead sponsor:** PYC Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-06-13
- **Primary completion:** 2025-09-23
- **Final completion:** 2025-11-24
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06455826

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06455826, "MAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects (Wallaby)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06455826. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*